Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer.
BRCA
HRD score
NGS
PARPi
breast cancer
early breast cancer
homologous recombination deficiency
metastatic breast cancer
mutational signature
platinum salts
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
18 Feb 2023
18 Feb 2023
Historique:
received:
13
12
2022
revised:
17
01
2023
accepted:
16
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
Breast cancer is the most frequently occurring cancer worldwide. With its increasing incidence, it is a major public health problem, with many therapeutic challenges such as precision medicine for personalized treatment. Thanks to next-generation sequencing (NGS), progress in biomedical technologies, and the use of bioinformatics, it is now possible to identify specific molecular alterations in tumor cells-such as homologous recombination deficiencies (HRD)-enabling us to consider using DNA-damaging agents such as platinum salts or PARP inhibitors. Different approaches currently exist to analyze impairment of the homologous recombination pathway, e.g., the search for specific mutations in homologous recombination repair (HRR) genes, such as
Identifiants
pubmed: 36831640
pii: cancers15041299
doi: 10.3390/cancers15041299
pmc: PMC9954086
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Ann Oncol. 2021 Dec;32(12):1582-1589
pubmed: 34500047
J Clin Oncol. 2020 May 10;38(14):1539-1548
pubmed: 32097092
J Natl Cancer Inst. 2011 Feb 16;103(4):334-46
pubmed: 21183737
J Biol Chem. 2018 Jul 6;293(27):10524-10535
pubmed: 29599286
J Natl Cancer Inst. 2000 Apr 5;92(7):564-9
pubmed: 10749912
Nat Rev Dis Primers. 2019 Sep 23;5(1):66
pubmed: 31548545
Cancers (Basel). 2021 Feb 28;13(5):
pubmed: 33670893
NPJ Breast Cancer. 2022 Mar 4;8(1):28
pubmed: 35246547
Breast Cancer Res. 2014 Jun 03;16(3):211
pubmed: 25093514
Breast Cancer Res Treat. 2012 Nov;136(2):487-93
pubmed: 23053638
Ann Oncol. 2018 May 1;29(5):1203-1210
pubmed: 29635390
Nature. 2017 Oct 19;550(7676):360-365
pubmed: 28976962
Life Sci. 2020 Nov 15;261:118434
pubmed: 32941897
Ann Oncol. 2021 Jan;32(1):49-57
pubmed: 33098995
Nat Commun. 2016 May 02;7:11383
pubmed: 27136393
Clin Cancer Res. 2018 Dec 15;24(24):6277-6287
pubmed: 30139880
Ann Oncol. 2020 May;31(5):590-598
pubmed: 32245699
Ann Oncol. 2018 Dec 1;29(12):2341-2347
pubmed: 30335131
Hered Cancer Clin Pract. 2019 Mar 25;17:11
pubmed: 30962858
Lancet. 2010 Jul 24;376(9737):235-44
pubmed: 20609467
Breast Cancer Res Treat. 2015 Jun;151(3):629-38
pubmed: 26006067
J Natl Compr Canc Netw. 2017 Oct;15(10):1216-1223
pubmed: 28982747
Cancer Res. 2012 Nov 1;72(21):5454-62
pubmed: 22933060
Nature. 2015 May 28;521(7553):489-94
pubmed: 26017449
Clin Cancer Res. 2017 Jul 1;23(13):3365-3370
pubmed: 28087643
Lancet Oncol. 2018 Apr;19(4):497-509
pubmed: 29501363
Front Oncol. 2022 Jun 17;12:880643
pubmed: 35785170
Cell Rep. 2013 Jan 31;3(1):246-59
pubmed: 23318258
Clin Cancer Res. 2016 Aug 1;22(15):3764-73
pubmed: 26957554
Breast Cancer Res. 2014 Dec 05;16(6):475
pubmed: 25475740
J Clin Oncol. 2020 Feb 10;38(5):388-394
pubmed: 31461380
Cell Cycle. 2012 Oct 15;11(20):3837-50
pubmed: 22983061
N Engl J Med. 2016 Jul 7;375(1):23-34
pubmed: 27406347
Nature. 2019 May;569(7757):560-564
pubmed: 31118521
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
Nat Methods. 2018 Feb;15(2):134-140
pubmed: 29256493
Cancer Discov. 2021 Nov;11(11):2812-2827
pubmed: 34045297
Expert Rev Mol Diagn. 2022 Feb;22(2):185-199
pubmed: 34913794
Clin Cancer Res. 2011 Mar 1;17(5):1082-9
pubmed: 21233401
Cell. 2017 Feb 9;168(4):644-656
pubmed: 28187286
Breast Cancer Res Treat. 2014 Sep;147(2):401-5
pubmed: 25129345
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Ann Oncol. 2021 Feb;32(2):240-249
pubmed: 33242536
Br J Cancer. 2012 Nov 6;107(10):1776-82
pubmed: 23047548
Nature. 2016 May 02;534(7605):47-54
pubmed: 27135926
Nat Med. 2018 May;24(5):628-637
pubmed: 29713086
J Clin Oncol. 2015 Jun 10;33(17):1895-901
pubmed: 25847929
Breast. 2018 Aug;40:141-146
pubmed: 29800932
FEBS Lett. 2010 Sep 10;584(17):3682-95
pubmed: 20655309
Clin Cancer Res. 2017 Dec 15;23(24):7521-7530
pubmed: 29246904
PLoS One. 2016 Apr 13;11(4):e0152500
pubmed: 27073890
Nature. 2005 Apr 14;434(7035):913-7
pubmed: 15829966
Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12871-6
pubmed: 14566050
J Pers Med. 2022 Feb 21;12(2):
pubmed: 35207810
Cancers (Basel). 2021 Jun 15;13(12):
pubmed: 34203855
Cancers (Basel). 2020 Sep 29;12(10):
pubmed: 33003546
J Clin Oncol. 2015 Jan 1;33(1):13-21
pubmed: 25092775
Nat Cancer. 2022 Aug;3(8):927-931
pubmed: 35788722
Nat Commun. 2014;5:3361
pubmed: 24553445
Sci Transl Med. 2016 Oct 26;8(362):362ps17
pubmed: 27797957
Sci Rep. 2020 Jul 27;10(1):12506
pubmed: 32719318
J Clin Invest. 1997 Apr 15;99(8):1947-57
pubmed: 9109439
Breast Cancer Res. 2012 Jul 20;14(4):R110
pubmed: 22817698
Lancet. 2010 Jul 24;376(9737):245-51
pubmed: 20609468
NPJ Syst Biol Appl. 2017 Mar 6;3:8
pubmed: 28649435
J Clin Oncol. 2015 Jan 20;33(3):244-50
pubmed: 25366685
Trends Mol Med. 2017 Dec;23(12):1121-1137
pubmed: 29133135
Cancer Discov. 2017 Sep;7(9):984-998
pubmed: 28588062
Eur J Cancer. 2021 Dec;159:283-295
pubmed: 34837859
J Clin Oncol. 2015 Jun 10;33(17):1902-9
pubmed: 25847936
J Clin Oncol. 2020 Dec 20;38(36):4274-4282
pubmed: 33119476
Clin Cancer Res. 2018 Sep 15;24(18):4482-4493
pubmed: 29858219
Ann Oncol. 2020 Nov;31(11):1518-1525
pubmed: 32798689
Lancet Oncol. 2017 Jan;18(1):75-87
pubmed: 27908594
Lancet Oncol. 2020 Sep;21(9):1155-1164
pubmed: 32771088
Clin Cancer Res. 2019 May 1;25(9):2717-2724
pubmed: 30563931
Cancer Discov. 2012 Apr;2(4):366-375
pubmed: 22576213
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Front Oncol. 2020 Nov 09;10:592998
pubmed: 33304851
Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84
pubmed: 18971340
Cancer Discov. 2015 Nov;5(11):1137-54
pubmed: 26463832
J Clin Oncol. 2018 Jun 10;36(17):1685-1694
pubmed: 29489427
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Br J Cancer. 2021 Jul;125(1):7-14
pubmed: 33767416
J Clin Med. 2020 Mar 30;9(4):
pubmed: 32235451
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
J Natl Cancer Inst. 2016 Jul 05;108(11):
pubmed: 27381626
Nature. 2008 Feb 28;451(7182):1116-20
pubmed: 18264087
JAMA Oncol. 2019 Aug 01;5(8):1132-1140
pubmed: 31194225
Lancet Oncol. 2020 Oct;21(10):1269-1282
pubmed: 32861273
NPJ Breast Cancer. 2017 Jul 20;3:27
pubmed: 28758147
Br J Cancer. 2019 Feb;120(4):398-403
pubmed: 30723304
Nat Commun. 2020 May 29;11(1):2662
pubmed: 32471999
Nat Cancer. 2022 Oct;3(10):1181-1191
pubmed: 36253484
Clin Cancer Res. 2014 Sep 15;20(18):4816-26
pubmed: 24963051
Ann Oncol. 2021 Dec;32(12):1590-1596
pubmed: 34520831
N Engl J Med. 2015 Oct 29;373(18):1697-708
pubmed: 26510020
Nat Rev Genet. 2014 Sep;15(9):585-98
pubmed: 24981601
EMBO Mol Med. 2018 Dec;10(12):
pubmed: 30377213
Oncologist. 2020 Mar;25(3):e439-e450
pubmed: 32162822
NPJ Breast Cancer. 2021 Nov 11;7(1):142
pubmed: 34764307
Lancet Oncol. 2017 Sep;18(9):1274-1284
pubmed: 28754483
Nat Genet. 2019 May;51(5):912-919
pubmed: 30988514
Nature. 2022 Oct;610(7931):343-348
pubmed: 36071165
N Engl J Med. 2021 Jun 24;384(25):2394-2405
pubmed: 34081848
JAMA Oncol. 2017 Oct 01;3(10):1378-1385
pubmed: 28715532
J Nucl Med. 2015 Jan;56(1):31-7
pubmed: 25476537
N Engl J Med. 2017 Dec 21;377(25):2490-2492
pubmed: 29262283
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
Int J Mol Sci. 2020 May 28;21(11):
pubmed: 32481735
Nat Med. 2017 Apr;23(4):517-525
pubmed: 28288110